Association between thyroid hormone levels, the number of circulating osteoprogenitor cells, and bone mineral density in euthyroid postmenopausal women
- PMID: 22075271
- DOI: 10.1016/j.metabol.2011.09.006
Association between thyroid hormone levels, the number of circulating osteoprogenitor cells, and bone mineral density in euthyroid postmenopausal women
Abstract
In postmenopausal women, an association between reduced bone mineral density (BMD) and increased number of circulating osteoprogenitor cells (COPs) has been found. Although an increased thyroid function is associated with BMD, thyroid hormones stimulate osteoblast function in vitro. We investigated whether thyroid hormones within the reference range were correlated with the number of COPs and stimulate mineralization in vitro. The number of COPs, defined as CD34+/alkaline phosphatase (AP)+ or CD34+/osteocalcin (OCN)+ cells, was quantified by fluorescence-activated cell sorting (FACS) analysis in 150 euthyroid postmenopausal women. Participants underwent measurement of serum free thyroxine (FT4), thyroid-stimulating hormone levels, and femur BMD. CD34+ cells were isolated from healthy volunteers irrespective of AP or OCN expression, and the effect of triiodothyronine (0.5-10 pmol/L)) on their ability to form mineralized nodules in vitro was studied. The number of COPs was highest among women with high-normal FT4 levels (>1.09 ng/dL). The FT4 levels were correlated positively with circulating log-CD34+/AP+ (r = 0.32, P < .001) and log-CD34/OCN+ cells (r = 0.36, P < .001) and inversely with total femur BMD (r = -0.17, P = .036) but not with femoral neck BMD. In a multivariate analysis, the FT4 levels were positively correlated with the number of COPs, independent of age and BMD. The ability of CD34+ cells to form mineralized nodules increased after exposure from low up to high-normal triiodothyronine concentrations (P for trend = .003). Among euthyroid postmenopausal women, high-normal FT4 levels are correlated with an increased number of circulating immature osteoprogenitor cells and a very mild BMD reduction. Exposure of CD34+ cells to physiological triiodothyronine concentrations stimulates mineralization in vitro.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Circulating immature osteoprogenitor cells and arterial stiffening in postmenopausal osteoporosis.Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):636-42. doi: 10.1016/j.numecd.2010.01.015. Epub 2010 May 31. Nutr Metab Cardiovasc Dis. 2011. PMID: 20554181
-
Association between circulating osteoblast progenitor cells and aortic calcifications in women with postmenopausal osteoporosis.Nutr Metab Cardiovasc Dis. 2013 May;23(5):466-72. doi: 10.1016/j.numecd.2011.08.006. Epub 2012 Feb 24. Nutr Metab Cardiovasc Dis. 2013. PMID: 22366195
-
Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis.Osteoporos Int. 2010 Feb;21(2):297-306. doi: 10.1007/s00198-009-0968-0. Epub 2009 May 30. Osteoporos Int. 2010. PMID: 19484167
-
Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.J Bone Miner Res. 2005 Mar;20(3):480-6. doi: 10.1359/JBMR.041126. Epub 2004 Nov 29. J Bone Miner Res. 2005. PMID: 15746993
-
Thyroid diseases and bone health.J Endocrinol Invest. 2018 Jan;41(1):99-109. doi: 10.1007/s40618-017-0753-4. Epub 2017 Aug 29. J Endocrinol Invest. 2018. PMID: 28853052 Free PMC article. Review.
Cited by
-
Emerging role of circulating calcifying cells in the bone-vascular axis.Circulation. 2012 Jun 5;125(22):2772-81. doi: 10.1161/CIRCULATIONAHA.112.090860. Circulation. 2012. PMID: 22665885 Free PMC article. Review. No abstract available.
-
Circulating osteogenic precursor cells: Building bone from blood.EBioMedicine. 2019 Jan;39:603-611. doi: 10.1016/j.ebiom.2018.11.051. Epub 2018 Dec 3. EBioMedicine. 2019. PMID: 30522933 Free PMC article. Review.
-
Association between thyroid autoimmunity and bone mineral density in patients with type 2 diabetes mellitus: a cross-sectional study.Endocrine. 2024 Aug;85(2):604-614. doi: 10.1007/s12020-024-03733-3. Epub 2024 Feb 23. Endocrine. 2024. PMID: 38393508
-
Development and validation of a new method to isolate, expand, and differentiate circulating osteogenic precursor (COP) cells.Bone Rep. 2021 Jul 22;15:101109. doi: 10.1016/j.bonr.2021.101109. eCollection 2021 Dec. Bone Rep. 2021. PMID: 34368409 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical